231 related articles for article (PubMed ID: 191876)
21. The effects of dextran sulfate, heparin and PGE1 on adenylate cyclase activity and aggregation of human platelets.
Reches A; Eldor A; Salomon Y
Thromb Res; 1979; 16(1-2):107-16. PubMed ID: 228444
[No Abstract] [Full Text] [Related]
22. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
23. Modulation of human gastric mucosal adenylate cyclase activity by prostacyclin.
Simon B; Kather H
Digestion; 1979; 19(2):137-9. PubMed ID: 383560
[TBL] [Abstract][Full Text] [Related]
24. Binding of 2-azidoadenosine [beta-32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase.
Macfarlane DE; Mills DC; Srivastava PC
Biochemistry; 1982 Feb; 21(3):544-9. PubMed ID: 6279146
[No Abstract] [Full Text] [Related]
25. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin stimulation of canine platelet adenylate cyclase.
Longenecker GL; Kopaciewicz LJ; Palmer SJ; Palmer GC
Thromb Res; 1980 Jul 1-15; 19(1-2):119-24. PubMed ID: 7444848
[No Abstract] [Full Text] [Related]
27. Inhibitory effects of S-(1,2-dicarboxyethyl)glutathione on collagen-induced platelet aggregation; enhancements of cyclic AMP level and adenylate cyclase activity in platelets by S-(1,2-dicarboxyethyl)glutathione.
Tsuboi S; Fujiwara E; Ogata K; Sakaue A; Nakayama T; Ohmori S
Biol Pharm Bull; 1993 Nov; 16(11):1083-6. PubMed ID: 8312859
[TBL] [Abstract][Full Text] [Related]
28. Regulation of platelet adenylate cyclase by adenosine.
Jakobs KH; Saur W; Johnson RA
Biochim Biophys Acta; 1979 Apr; 583(4):409-21. PubMed ID: 427219
[TBL] [Abstract][Full Text] [Related]
29. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides.
Gryglewski RJ; Bunting S; Moncada S; Flower RJ; Vane JR
Prostaglandins; 1976 Nov; 12(5):685-713. PubMed ID: 824685
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor).
Haslam RJ; Vanderwel M
J Biol Chem; 1982 Jun; 257(12):6879-85. PubMed ID: 6177688
[No Abstract] [Full Text] [Related]
31. Prostaglandin E1 action on adenylate cyclase activity and membrane lipids in platelets.
Mruk J; Bakardjiev A; Burgermeister W
Hoppe Seylers Z Physiol Chem; 1982 Jul; 363(7):745-56. PubMed ID: 6957369
[TBL] [Abstract][Full Text] [Related]
32. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
[TBL] [Abstract][Full Text] [Related]
33. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
Salzman EW
Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
[TBL] [Abstract][Full Text] [Related]
34. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
[TBL] [Abstract][Full Text] [Related]
35. Desensitization of prostaglandin-activated platelet adenylate cyclase.
Cooper B; Schafer AI; Puchalsky D; Handin RI
Prostaglandins; 1979 Apr; 17(4):561-71. PubMed ID: 461820
[TBL] [Abstract][Full Text] [Related]
36. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
Nogimori K; Kajikawa N; Nishio S; Yajima M
Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
[TBL] [Abstract][Full Text] [Related]
37. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action.
Seiler SM; Brassard CL; Federici ME; Buchanan JO; Zavoico GB; Fleming JS; Meanwell NA
Thromb Res; 1994 Apr; 74(2):115-23. PubMed ID: 8029812
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives.
Harris DN; Asaad MM; Phillips MB; Goldenberg HJ; Antonaccio MJ
J Cyclic Nucleotide Res; 1979; 5(2):125-34. PubMed ID: 221552
[TBL] [Abstract][Full Text] [Related]
39. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
40. The influence of prostaglandin endoperoxides on platelet ultrastructure.
Gerrard JM; White JG
Am J Pathol; 1975 Aug; 80(2):189-202. PubMed ID: 169697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
